ArticleExploratory research in clinical and social pharmacy2025
Impact of mRNA COVID-19 vaccination on hematological parameters in patients maintained on clozapine: A retrospective study from Qatar.
Article in Exploratory research in clinical and social pharmacy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: COVID-19 vaccines are known to cause transient changes in white blood cell counts as part of the immune activation process. Clozapine, an antipsychotic agent primarily prescribed for treatment-resistant schizophrenia, possesses both immunosuppressive and pro-inflammatory properties that may influence vaccine-related immune responses. The concurrent use of clozapine during COVID-19 vaccination has therefore raised concerns regarding potential hematological adverse effects. Despite increasing global research in this area, data from Arab populations remain scarce, highlighting the need for region-specific evidence. This study aimed to investigate the incidence of white blood cell and absolute neutrophil count abnormalities in patients receiving clozapine who were vaccinated with mRNA COVID-19 vaccines. Method: A retrospective study was conducted within Qatar's public mental health services. The study included patients on clozapine who received at least one dose of a COVID-19 vaccine between February 2020 and November 2022. Hematological parameters were assessed at three time points: pre-vaccination, shortly post-vaccination, and three months post-vaccination. Demographic, clinical, and vaccine-related factors were also examined. Results: Of 111 vaccinated patients, 74 had complete blood test data across the three time points. No cases of agranulocytosis or other serious hematological adverse effects were observed. Mild leukopenia occurred in 6.8-8.1 % of patients, and mild neutropenia in 5.4-6.8 %. These changes were transient and not associated with clozapine dosage, vaccine type, or other clinical variables. Conclusion: COVID-19 mRNA vaccines appear safe for individuals maintained on clozapine, with only minor, temporary changes in white blood cell counts. These findings support continued vaccination efforts in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.